Description
A GPIIb/IIIa antagonist (IC50 = 5 nM in a radioligand binding assay); inhibits GPIIb/IIIa-dependent platelet aggregation (IC50 = 11 nM); inhibits HUVEC attachment to microtiter plates containing Fg, Vn, or Fn at concentrations >10,000-fold above the IC50 for platelet aggregation; prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis
Formal name: N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine, monohydrochloride, monohydrate
Synonyms:
Molecular weight: 495.1
CAS: 150915-40-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Blood|Acute Phase Reactants||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Blood|Thrombosis||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Vasculature|Angiogenesis